Items where SHU Author is "Lawson, Kim"

LAWSON, Kim (2022). Identification of the Involvement of Potassium Channels in Fibromyalgia. Frontiers in Bioscience-Scholar, 14 (4): 29.

FURNESS, Penny, SHELTON, Tom, BERESFORD, Ruth, LAWSON, Kim, TAYLOR, Sophie and HAYWOOD-SMALL, Sarah (2022). Remote care for chronic pain: A qualitative evaluation with managers, practitioners and patients. Journal of Pain Management, 15 (4).

FURNESS, Penelope, SHELTON, Tom, BERESFORD, Ruth, LAWSON, Kim, TAYLOR, Sophie and HAYWOOD-SMALL, Sarah (2022). Physiotherapy for fibromyalgia: a phenomenological study of patients’ experiences. Journal of Pain Management, 15 (4).

PIRAGINE, Eugenia, CITI, Valentina, LAWSON, Kim, CALDERONE, Vincenzo and MARTELLI, Alma (2022). Potential Effects of Natural H2S-Donors in Hypertension Management. Biomolecules, 12 (4): 581.

PIRAGINE, Eugenia, CITI, Valentina, LAWSON, Kim, CALDERONE, Vincenzo and MARTELLI, Alma (2022). Potential effects of natural H 2 S-Donors in Hypertension Management. Biomolecules, 12 (4): 581.

LAWSON, Kim, SINGH, Attam, KANTSEDIKAS, Ilya, JENNER, Christopher Arthur and AUSTEN, Daniel Keith (2021). Flupirtine as a Potential Treatment for Fibromyalgia. Journal of Exploratory Research in Pharmacology.

TAYLOR, Sophie, FURNESS, Penny, ASHE, Simon, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2021). Comorbid Conditions, Mental Health and Cognitive Functions in Adults with Fibromyalgia. Western Journal of Nursing Research, 43 (2), 115-122.

LAWSON, Kim (2020). Sleep Dysfunction in Fibromyalgia and Therapeutic Approach Options. OBM Neurobiology, 4 (1), p. 16.

LAWSON, Kim (2019). Is there a role for melatonin in fibromyalgia? AIMS Molecular Science, 6 (4), 73-86.

LAWSON, Kim (2019). Pharmacology and clinical applications of flupirtine: Current and future options. World journal of pharmacology, 8 (1), 1-13.

LAWSON, Kim (2018). Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis. World Journal of Pharmacology, 7 (1), 1-9.

TAYLOR, Sophie, STEER, Michael, ASHE, Simon, FURNESS, Penny, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2018). Patients' perspective of the effectiveness and acceptability of pharmacological and non-pharmacological treatments of fibromyalgia. Scandinavian Journal of Pain.

FURNESS, Penny, VOGT, Katharina, ASHE, Simon, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2018). What causes Fibromyalgia? An online survey of patient perspectives. Health Psychology Open, 5 (2).

LAWSON, Kim (2018). Flupirtine is an effective analgesic: is the associated rare liver injury a limiting factor to its use? Anesthesia and Analgesia.

ASHE, Simon, FURNESS, Penny, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2017). A qualitative exploration of the experiences of living with and being treated for fibromyalgia. Health Psychology Open, 4 (2), 1-12.

LAWSON, Kim (2017). A brief review of the pharmacology of amitriptyline and clinical outcomes in treating fibromyalgia. Biomedicines, 5 (2), p. 24.

LAWSON, Kim (2017). Emerging pharmacological strategies for the treatment of fibromyalgia. World Journal of Pharmacology, 6 (1), 1-10.

ASHE, Simon, FURNESS, Penny, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2016). "Not all in my head": a qualitative exploration of living with fibromyalgia and its treatments (Oral presentation). The European Health Psychologist, 18 (Supp), p. 695.

LAWSON, Kim (2016). Fibromyalgia pathogenesis provides drug target clues. Drug Target Review, 3, 45-49.

LAWSON, Kim (2016). Potential drug therapies for the treatment of fibromyalgia. Expert opinion on investigational drugs, 1-11.

LAWSON, Kim (2014). Clinical trials for patients with fibromyalgia syndrome. Clinical & Experimental Pharmacology, 04 (05).

MARTELLI, A., TESTAI, L., BRESCHI, M.C., LAWSON, Kim, MCKAY, Neil, MICELI, F., TAGLIALATELA, M. and CALDERONE, V. (2013). Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. Pharmacological Research, 70 (1), 27-34.

BEARD, S M, ROSKELL, N, LE, T K, ZHAO, Y, COLEMAN, A, ANG, D and LAWSON, Kim (2011). Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. Journal of medical economics.

VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2011). Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: effect of potassium channel modulators. European Journal of Pharmacology, 660 (2-3), 431-437.

PUTTINI, P. Sarzi, HÄUSER, W., LAWSON, Kim and SPROTT, H. (2009). 11 Topical Seminar Summary: FIBROMYALGIA SYNDROME. European Journal of Pain, 13, S5-S6.

VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2009). Cholinergic modulation of spontaneous activity in bladder strips from the diabetic rat : effect of the mucosa. European Eurology Supplements, 8 (4), p. 177.

VAHABI, B., MCKAY, Neil, LAWSON, Kim and SELLERS, Donna (2008). Identification of C-Kit positive cells in rat urinary bladder and characterization of their functional role in spontaneous activity in control and diabetic bladders. European Eurology Supplements, 7 (3), p. 181.

SELLERS, Donna, MCKAY, Neil and LAWSON, Kim (2008). Inhibitory effect of cromakalim on muscarinic receptor-stimulated spontaneous activity in diabetic rat bladder. Fundamental & Clinical Pharmacology, 22 (Suppl), p34.

MCKAY, Neil, KIRBY, R W and LAWSON, Kim (2008). Rubidium efflux as a tool for the pharmacological characterisation of compounds with BK channel opening properties. In: LIPPIAT, Jonathan D, (ed.) Potassium channels : methods and protocols. Methods in Molecular Biology (491). Humana Press, 267-277.

LAWSON, Kim (2007). Are complex therapies required as pharmacological treatments of fibromyalgia? Future Rheumatology, 2 (6), 599-605.

LAWSON, Kim (2006). Emerging pharmacological therapies for fibromyalgia. Current Opinion in Investigational Drugs, 7 (7), 631-636.

LAWSON, Kim (2006). Potassium channels as targets for the management of pain. Central Nervous System Agents in Medicinal Chemistry, 6 (2), 119-128.

LAWSON, Kim (2002). Tricyclic antidepressants and fibromyalgia: what is the mechanism of action? Expert opinion on investigational drugs, 11 (10), 1437-1445.

LAWSON, Kim and DUNNE, Mark J. (2001). Peripheral channelopathies as targets for potassium channel openers. Expert opinion on investigational drugs, 10 (7), 1345-1359.